USMCA Trade Negotiations: Could US House Dems' Talks Open Door For AAM Changes?

Biologics exclusivity remains a contentious issue as US Trade Representative and House Democrats begin discussions on the trade pact with Mexico and Canada.  

United States Mexico Canada Agreement, USMCA concept. 3D rendering

When the United States-Mexico-Canada Agreement was signed in November, it seemed like the Association for Accessible Medicines and other stakeholders faced an uphill battle to alter its provisions. But some members of the US Congress were sympathetic to their arguments, with House Democrats, for example, setting up working groups to engage in further discussions with the US Trade Representative.

And during a recent Senate hearing, some legislators expressed concerns that the USMCA trade pact could limit their options to...

More from Legislation

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By 

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.